Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers

DNA Cell Biol. 2007 Jul;26(7):453-63. doi: 10.1089/dna.2007.0585.


Tumor growth, which employs a number of regulators, requires the formation of new blood vessels. The most important regulators are vascular endothelial growth factor (VEGF) and angiopoietin-2 (ANGPT-2). DNA sequence variations in VEGF and ANGPT-2 genes may lead to altered productions and/or activities of these genes. In this study, we aimed to determine the polymorphic effects of the changes in the VEGF -460 C/T, VEGF 936 C/T, and ANGPT-2 exon 4 G/A, which we perceive as risk factors in the progress and metastasis of cancer, on the gynecologic cancer patients in the Turkish population. Forty-seven ovarian, 32 cervical, and 21 endometrial cancer patients and 106 healthy controls were studied. The genomic DNA was extracted from the whole blood by using DNA extraction techniques. DNA samples were analyzed by polymerase chain reaction and restriction fragment length polymorphism. There were no significant differences between any of the three types of gynecologic cancer patients and controls in terms of the distribution of VEGF -460, VEGF 936, and ANGPT-2 genotypes and alleles (p > 0.05). Odds ratios (ORs) were calculated by logistic regression analysis in comparison with the most common homozygote genotype observed in the studied population. No evidence of a relationship that would constitute a risk factor (p > 0.05) was found between genotype and allele frequencies of patients and controls for VEGF -460, VEGF 936, and ANGPT-2 genes. A multivariable logistic regression analysis with the involvement of covariant factors, such as the history of gynecologic cancer and/or other cancer types in the family, stages of tumor, smoking habits, and existence of other diseases, did not change the results. The present study is the first case-control study of VEGF and ANGPT-2 polymorphisms in relation to ovarian, cervical, and endometrial cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiopoietin-2 / genetics*
  • DNA Primers
  • DNA, Neoplasm / genetics
  • Endometrial Neoplasms / blood supply
  • Endometrial Neoplasms / genetics*
  • Endometrial Neoplasms / pathology
  • Exons*
  • Female
  • Genetic Variation
  • Genotype
  • Humans
  • Middle Aged
  • Neovascularization, Pathologic / genetics
  • Ovarian Neoplasms / blood supply
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / pathology
  • Polymerase Chain Reaction
  • Polymorphism, Single Nucleotide*
  • Risk Factors
  • Uterine Cervical Neoplasms / blood supply
  • Uterine Cervical Neoplasms / genetics*
  • Uterine Cervical Neoplasms / pathology
  • Vascular Endothelial Growth Factor A / genetics*


  • Angiopoietin-2
  • DNA Primers
  • DNA, Neoplasm
  • Vascular Endothelial Growth Factor A